Baseline characteristics
| Characteristic . | Placebo median (IQR) n = 22 . | Maraviroc median (IQR) n = 23 . |
|---|---|---|
| Age, years | 50 (43-57) | 50 (46-56) |
| Male gender, no. (%) | 20 (91) | 23 (100) |
| Ethnicity, no. (%) | ||
| White/European American | 14 (64) | 13 (57) |
| Black/African American | 4 (18) | 6 (26) |
| Hispanic/Latino | 3 (14) | 4 (17) |
| Asian | 1 (5) | 0 (0) |
| CD4+ T-cell count, cells per mm3 | 202 (161-256) | 206 (131-260) |
| Self-reported nadir CD4 count, cells per mm3 | 21 (8-41) | 30 (3-90) |
| Plasma HIV RNA level, copies per mL | <48 | <48 |
| Duration of current ART regimen, months | 31 (15-43) | 30 (21-42) |
| Hepatitis C virus antibody positive, no. (%) | 3 (14) | 4 (21) |
| Serum AST level, mg/dL | 27 (22-31) | 25 (17-30) |
| Serum ALT level, mg/dL | 32 (24-41) | 34 (22-41) |
| Characteristic . | Placebo median (IQR) n = 22 . | Maraviroc median (IQR) n = 23 . |
|---|---|---|
| Age, years | 50 (43-57) | 50 (46-56) |
| Male gender, no. (%) | 20 (91) | 23 (100) |
| Ethnicity, no. (%) | ||
| White/European American | 14 (64) | 13 (57) |
| Black/African American | 4 (18) | 6 (26) |
| Hispanic/Latino | 3 (14) | 4 (17) |
| Asian | 1 (5) | 0 (0) |
| CD4+ T-cell count, cells per mm3 | 202 (161-256) | 206 (131-260) |
| Self-reported nadir CD4 count, cells per mm3 | 21 (8-41) | 30 (3-90) |
| Plasma HIV RNA level, copies per mL | <48 | <48 |
| Duration of current ART regimen, months | 31 (15-43) | 30 (21-42) |
| Hepatitis C virus antibody positive, no. (%) | 3 (14) | 4 (21) |
| Serum AST level, mg/dL | 27 (22-31) | 25 (17-30) |
| Serum ALT level, mg/dL | 32 (24-41) | 34 (22-41) |
ALT, alanine aminotransferase; AST, aspartate aminotransferase.